分析盆腔弥漫性大B细胞淋巴瘤的诊治要点。通过对一例盆腔弥漫性大B细胞淋巴瘤患者的病例进行详尽的回顾性研究,并复习了相关文献。该病例为女性,74岁,初期症状为绝经后阴道出血,经活检病理诊断为弥漫性大B细胞淋巴瘤,治疗方案包括前三个周期泼尼松(POLA-R-CDP),维泊妥珠单抗联合利妥昔单抗,多柔比星和环磷酰胺。接下来的第4~6周期,患者接受了环磷酰胺,长春新碱(R-CHOP),利妥昔单抗,阿霉素的化疗方案,第7周期的治疗为利妥昔单抗联合大剂量甲氨蝶呤(HDMTX)。在第8周期,患者接受了阿糖胞苷、鞘内注射地塞米松和甲氨蝶呤。目前,患者的病灶已显著减小,且未观察到复发迹象。盆腔淋巴瘤是一种罕见的疾病,通常表现为无特异性在临床上,治疗方面现推荐6~8轮R-CHOP + 放疗(45 Gy) (Radiotherapy, RT) ± 手术治疗,对于高度怀疑该病的病例应尽早明确诊断,治疗方式的选择至关重要。To investigate the diagnosis and treatment of pelvic diffuse large B-cell lymphoma. A case of pelvic diffuse large B-cell lymphoma was analyzed retrospectively and the literature was reviewed. The patient, a 74-year-old female, presented with postmenopausal vaginal bleeding as the initial symptom and was diagnosed with diffuse large B-cell lymphoma by biopsy and pathology. She received the chemotherapy regimen of Vepostuzumab combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CDP) at the first 1~3 cycles. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine (R-CHOP) regimen at cycle 4~6, rituximab combined with high-dose methotrexate (HDMTX) at cycle 7, intravaginal injection of dexamethasone, cytarabine, and methotrexate at cycle 8, the patient’s lesions were significantly smaller than before, and no signs of recurrence were observed. Pelvic lymphoma is an extremely rare disease with non-specific clinical manifestations, and 6~8 rounds of R-CHOP + Radiotherapy (45
